Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

DATROWAY: unresectable metastatic Breast cancer with PD-L1 stated without a specific alteration

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ].

Broader topic: Breast Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
  1. gene
    PD-L1
    alteration
    stated without a specific alteration
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for DATROWAY (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ].

    Study evidence for this setting

    3 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT02425891 · Source cited / selected · Scope: unclear

    A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Ca

    6 outcome links · 2 safety-group records · 2 quality-of-life measures

    →

    NCT03125902 · Source cited / selected · Scope: unclear

    A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

    6 outcome links · 2 safety-group records · 1 quality-of-life measures

    →

    NCT03498716 · Source cited / selected · Scope: unclear

    A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple

    6 outcome links · 2 safety-group records · 3 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice